

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – March 8, 2023 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Jennifer de los Angeles –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 952 7560 1667

Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. February 8, 2023 DUR Board Meeting Minutes
- B. February 8, 2023 DUR Board Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Moss, Dr. Kottoor, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Spring 2023 Pipeline Update – See Appendix B

- A. Pharmacy Helpdesk Activity for February 2023
- B. Medication Coverage Activity for February 2023
- C. Spring 2023 Pipeline Update

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Brimonidine 0.33% Topical Gel (Generic Mirvaso®), Vtama® (Tapinarof), and Zoryve™ (Roflumilast) and Update the Approval Criteria for Topical Acne, Psoriasis, and Rosacea Products – See Appendix C

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Tadliq® (Tadalafil Oral Suspension) and Tyvaso DPI® (Treprostinil Powder for Inhalation) and Update the Approval Criteria for the Pulmonary Hypertension Medications – See Appendix D

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Zonisade™ (Zonisamide Oral Suspension) and Ztalmy® (Ganaxolone) and Update the Approval Criteria for the Anticonvulsants – See Appendix E

- A. Market News and Updates
- B. Ztalmy® (Ganaxolone) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Rezlidhia™ (Olutasidenib) and Update the Approval Criteria for the Leukemia Medications – See Appendix F

- A. Market News and Updates
- B. Rezlidhia™ (Olutasidenib) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

9. Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Jaypirca™ (Pirtobrutinib) and Lunsumio™ (Mosunetuzumab-axgb) – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Lymphoma Medications
- C. Prior Authorization of Lymphoma Medications
- D. Market News and Updates
- E. Jaypirca™ (Pirtobrutinib) Product Summary
- F. Lunsumio™ (Mosunetuzumab-axgb) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Lymphoma Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

10. Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and 30-Day Notice to Prior Authorize Rolvedon™ (Eflapegrastim-xnst) and Stimufend® (Pegfilgrastim-fpgk) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of G-CSFs
- C. Prior Authorization of G-CSFs
- D. Market News and Updates

- E. Cost Comparison
- F. College of Pharmacy Recommendations
- G. Utilization Details of G-CSFs

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

11. Annual Review of Growth Hormone Products and Voxzogo® (Vosoritide) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Growth Hormone Products and Voxzogo® (Vosoritide)
- C. Prior Authorization of Growth Hormone Products and Voxzogo® (Vosoritide)
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Growth Hormone Products and Voxzogo® (Vosoritide)

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

12. 30-Day Notice to Prior Authorize Lamzede® (Velmanase Alfa-tycv) – See Appendix J

- A. Introduction
- B. Lamzede® (Velmanase Alfa-tycv) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

13. Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Briumvi™ (Ublituximab-xiiy), Tascenso ODT® [Fingolimod Orally Disintegrating Tablet (ODT)] – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of MS Medications
- C. Prior Authorization of MS Medications
- D. Market News and Updates
- E. Briumvi™ (Ublituximab-xiiy) Product Summary
- F. Cost Comparison: Fingolimod Products
- G. College of Pharmacy Recommendations
- H. Utilization Details of MS Medications

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

14. Annual Review of Short-Acting Beta₂ Agonists (SABAs) and 30-Day Notice to Prior Authorize Airsupra™ (Albuterol/Budesonide) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of SABAs
- C. Prior Authorization of SABAs
- D. Market News and Updates
- E. Airsupra™ (Albuterol/Budesonide) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of SABAs

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

15. Annual Review of Urea Cycle Disorder (UCD) Medications and 30-Day Notice to Prior Authorize Olpruva™ (Sodium Phenylbutyrate Pellets for Oral Suspension) and Pheburane® (Sodium Phenylbutyrate Oral Pellets) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of UCD Medications
- C. Prior Authorization of UCD Medications
- D. Market News and Updates
- E. Cost Comparison: UCD Medications
- F. College of Pharmacy Recommendations
- G. Utilization Details of UCD Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)

- A. Anti-Diabetic Medications
- B. Anti-Emetic Medications
- C. Lung Cancer Medications
- D. Systemic Antifungal Medications

*Future product and class reviews subject to change.

18. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.